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Abstract
Background: High-risk prescribing of non-steroidal anti-inflammatory drugs (NSAIDs) and antiplatelet agents
accounts for a significant proportion of hospital admissions due to preventable adverse drug events. The recently
completed PINCER trial has demonstrated that a one-off pharmacist-led information technology (IT)-based
intervention can significantly reduce high-risk prescribing in primary care, but there is evidence that effects
decrease over time and employing additional pharmacists to facilitate change may not be sustainable.
Methods/design: We will conduct a cluster randomised controlled with a stepped wedge design in 40 volunteer
general practices in two Scottish health boards. Eligible practices are those that are using the INPS Vision clinical IT
system, and have agreed to have relevant medication-related data to be automatically extracted from their
electronic medical records. All practices (clusters) that agree to take part will receive the data-driven quality
improvement in primary care (DQIP) intervention, but will be randomised to one of 10 start dates. The DQIP
intervention has three components: a web-based informatics tool that provides weekly updated feedback of
targeted prescribing at practice level, prompts the review of individual patients affected, and summarises each
patient’s relevant risk factors and prescribing; an outreach visit providing education on targeted prescribing and
training in the use of the informatics tool; and a fixed payment of 350 GBP (560 USD; 403 EUR) up front and a
small payment of 15 GBP (24 USD; 17 EUR) for each patient reviewed in the 12 months of the intervention. We
hypothesise that the DQIP intervention will reduce a composite of nine previously validated measures of high-risk
prescribing. Due to the nature of the intervention, it is not possible to blind practices, the core research team, or
the data analyst. However, outcome assessment is entirely objective and automated. There will additionally be a
process and economic evaluation alongside the main trial.
Discussion: The DQIP intervention is an example of a potentially sustainable safety improvement intervention that
builds on the existing National Health Service IT-infrastructure to facilitate systematic management of high-risk
prescribing by existing practice staff. Although the focus in this trial is on Non-steroidal anti-inflammatory drugs
and antiplatelets, we anticipate that the tested intervention would be generalisable to other types of prescribing if
shown to be effective.
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Background
Importance of high-risk prescribing of non-steroidal anti-
inflammatory drugs and antiplatelets
The quality and safety of prescribing in primary care is
an area of increasing concern in the UK and interna-
tionally. A number of systematic reviews, including large
scale studies conducted in the UK, have demonstrated
deficits in the safety and quality of medication use to a
degree, which constitutes a public health threat: 3% to
4% of all unplanned hospital admissions are caused by
preventable adverse drug events [1,2]. Antiplatelets,
non-steroidal anti-inflammatory drugs (NSAIDs), oral
anticoagulants, diuretics, and other potentially nephro-
toxic agents account for approximately 60% of all pre-
ventable admissions.
It is important to distinguish ‘high-risk’ from ‘inap-
propriate’ prescribing, because there will be situations
where prescribers and patients are struggling to best
manage complex problems for which there is no clearly
correct action, and high-risk prescriptions may be justi-
fied. However, high-risk prescribing requires systematic
management and regular review in order to minimise
harm. Effective strategies are therefore needed that
enable practitioners to continuously identify, review, and
monitor high-risk prescribing [3].
One approach to identifying and reducing high-risk
prescribing is the assessment of medication use against
explicit measures, thereby highlighting patients who are
at risk of adverse outcomes and require a review of ben-
efits and risks. In the UK and internationally, this
approach is facilitated by the increasing implementation
of electronic patient records in primary care, which
enable routine screening for patients at risk of preventa-
ble adverse drug events. Such an approach requires, as a
minimum, focussing on those quality and safety pro-
blems that are strongly linked to patient outcomes
based on research evidence [4].
Our previous research has defined and validated a
broad set of explicit measures for the assessment of pre-
scribing quality and safety in primary care [5]. In accor-
dance with research evidence, the ‘use of antiplatelets
and oral NSAIDs in patients at increased risk of gastro-
intestinal bleeding’ and ‘use of oral NSAIDs in patients
at increased risk of renal failure’ were identified as key
priorities for quality improvement in primary care by a
Delphi panel of primary care clinicians [5]. We have
shown that this prescribing is both common and highly
variable between practices, which generally indicates
scope for improvement [6].
Rationale for the Data-driven Quality Improvement in
Primary care (DQIP) intervention
There is a large body of research examining changing
professional practice to improve the quality of care,
much of which has been systematically reviewed [7,8]. A
significant proportion of this research relates to improv-
ing prescribing [9,10]. Although not all studies show
positive effects, there is good evidence for small (~5%)
to moderate (11% to 20%) effects of a number of quality
improvement strategies. Multi-faceted interventions
appear to be more effective than single strategy ones.
Strategies shown to be effective include the use of:
1. Feedback of performance data [7], particularly if
feedback is prolonged rather than one - off [11].
2. Educational outreach visits, where the evidence is
particularly consistent for improving prescribing [8].
3. Interactive educational workshops for continuing
professional development [12].
4. Informatics to support clinician decision making
and implementation of guidelines [13,14], particularly
where it is integrated into existing systems [15].
The broad conclusion of this research is that profes-
sional practice can be changed, but that improvements
in care are not guaranteed with any strategy and are
sometimes short-lived. For example, the PINCER trial
recently examined the impact of simple feedback versus
pharmacists working in general practices for 12 weeks,
delivering education and supporting the review of
patients with apparent deficiencies in prescribing or
monitoring. Significant reductions in all three primary
outcome measures at six months follow-up, but for one
(high-risk prescribing of NSAIDs in patients with a his-
tory of peptic ulcer), the effect size was smaller and
non-significant at 12 months, possibly reflecting that the
active intervention was one-off and took place early at
the start of the follow-up year [16].
With the spread of electronic medical records and
improvements in the information technology (IT) infra-
structure, it is increasingly feasible to continuously mea-
sure prescribing quality and safety. This allows for
timely data feedback and enables practices to identify
patients who are currently at risk of preventable drug
related harm. On the basis of this information, practices
can develop a strategy for systematic patient review and
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monitor trends of high-risk prescribing at practice level
that allows unfavourable trends to be exposed and
addressed.
Trial design
The research team will deliver the DQIP intervention to
general practices with the intention of changing profes-
sional behaviour, and cluster randomisation at practice
level will therefore be used. The trial will use the
stepped wedge design [17,18], with all participating
practices receiving the DQIP intervention, but rando-
mised to one of ten different start dates and with each
practice functioning as their own control in a time series
analysis. Practices will only have access to the DQIP tool
over the duration of the trial (48 weeks), so that out-
come measures during the DQIP intervention will be
compared to care prior to it. Practices will be rando-
mised to start the intervention at four weekly intervals
with planned gaps to avoid Christmas/New Year and
March (the end of the QOF reporting year). The
stepped wedge design as it is used in this trial is illu-
strated in Figure 1.
Methods
Participants and settings
The trial will be conducted in volunteer practices in two
Scottish health boards, NHS Tayside and NHS Fife.
These two Boards provide healthcare for approximately
700,000 patients, with direct responsibility for hospital
and community services, and holding the contracts for
independent contractors including general practice.
Primary medical care is provided by ~130 general prac-
tices, and both Boards have a variety of ways in which
they seek to influence general practice prescribing,
including the use of formularies, guidelines, newsletters,
prescribing advice, and the use of primary care
pharmacists.
Prescribing advice and primary care pharmacist input
varies significantly between the two Boards. In Tayside,
there is a greater primary care pharmacy resource in the
sense that each practice has a dedicated (usually part-
time) primary care pharmacist who works on a mixture
of community health partnership and/or Board priori-
ties, and projects agreed with the practice. In Fife, these
functions are split between development pharmacists
who work at locality level (five localities across three
community health partnerships) providing prescribing
advice and facilitated discussion of prescribing data, and
primary care pharmacists who work in practices,
although typically for fewer hours than in Tayside.
In both Boards, general practitioners (GPs) take
responsibility for virtually all community prescribing,
although nurses, health visitors, and pharmacists are
increasingly prescribing some medicines under defined
protocols (although this is currently only a small pro-
portion of total prescribing). The intervention therefore
targets existing teams of professionals working in gen-
eral practices in NHS Tayside and NHS Fife.
Practice inclusion criteria
Practice inclusion criteria include general medical prac-
tices in NHS Fife and NHS Tayside using the INPS
Cohort 1
Cohort 2
Cohort 3
Cohort 4
Cohort 5
Cohort 6
Cohort 7
Cohort 8
Cohort 9
Cohort 10
Pre-intervention  period 
with measurement  
 every 8 weeks 
Intervention period  
   with measurement  
       every 8 weeks 
Intervention  
      starts 
Time (each box is 8 weeks) 
Intervention  
      ends 
Figure 1 Illustration of the stepped wedge design. Each rectangle represents an eight-week time period. Practices are randomised to start
the intervention in blocks of four, with measurement of outcome for 48 weeks every eight weeks before the intervention starts and during the
48 weeks of the intervention.
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Vision clinical IT system (n = 78) and agreeing to parti-
cipate, and practices that agree to have relevant medica-
tion related data to be automatically extracted from
their electronic clinical information systems
Practice exclusion criteria
Practices that use GPASS or EMIS clinical IT systems
on the date of randomisation will be excluded, because
data extraction for the informatics requires the INPS
Vision clinical IT system
Components of the DQIP intervention
The DQIP intervention has three components (Figure 2).
Intervention component one: Informatics tool
The informatics tool is central to the intervention, and
will involve the extraction of existing GP clinical data to
an NHS Tayside database accessible to the DQIP infor-
matics tool developed by Aridhia (an IT company con-
tracted by NHS Tayside for this purpose). The
informatics component will:
1. Summarise numbers of patients affected by high-
risk prescribing at practice level based on nine validated
measures and one composite measure (see outcome
measures). This will allow each practice to monitor
trends in high-risk prescribing before and after the start
of the DQIP intervention.
2. Identify patients affected by high-risk prescribing
for review by the practice, and allow practices to select
which patients to target first (e.g., patients triggering
particular measures, patients triggering multiple
measures).
3. Structure clinical information to facilitate review.
All decisions about prescribing and organisation of work
around DQIP remain a practice responsibility, including
deciding which professional is most suited to do any
initial record-based review and any follow-up telephone
or face-to-face review.
4. Record review decisions using structured data that
supports re-identification of patients if necessary, and to
measure trial processes for evaluation.
Figure 2 Illustration of intervention components and desired impact on prescribing behavior.
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5. Support reminders to practices to review their data
via e-mail reminders.
6. Support the educational intervention (provide gen-
eral information/summaries of the evidence of risk, links
to more detailed reference information, prevalence mea-
surement, and run charts for each practice).
The DQIP informatics tool will additionally collect
data for trial process evaluation and record data to trig-
ger practice payment at the end of the trial.
The data held in the NHS Tayside database will be
identifiable, and access to it will be controlled in the
same way that NHS Tayside controls access to all
patient identifiable data (e.g., in Central Vision and
other web-based patient information systems), with indi-
vidual user accounts created at the request of each prac-
tice. In NHS Tayside, access will be controlled using the
standard lightweight directory access protocol (LDAP)
account that primary care clinicians use to access all
NHS Tayside clinical databases and tools. In NHS Fife,
users will receive a Tayside LDAP guest account with
access exclusively granted to the DQIP informatics tool
(the exception will be practices in North East Fife which
use the Ninewells laboratory and already have Tayside
LDAP accounts for Central Vision access). Only prac-
tice-based users will have access to identifiable patient
information in the informatics tool. For DQIP purposes,
a practice-based user is defined as a professional that
the practice nominates as an appropriate user, and is
expected to include GPs, the practice manager, and (in
some cases) primary care pharmacists (who are not
practice employees, but often work clinically in prac-
tices). With practice permission, the research team will
have access to aggregate practice data (prevalence and
run charts) during the trial for trial management pur-
poses, and to anonymised patient level data after the
trial ends for analysis.
Intervention component two: Educational outreach
The educational intervention will aim to:
1. Clarify the risk of the targeted prescribing and per-
suade professionals in participating practices that this
prescribing is risky by providing general information
with references and links to more detailed information.
2. Persuade professionals that the targeted prescribing
is a potential problem in their practice by feeding back
prevalence via Tables and run charts.
3. Engage professional/internal motivation to do a
‘good job’ by persuading professionals that the purpose
of the intervention is better patient care, and that this is
activity that practices should engage in by appealing to
professional values and by creating implicit behavioural
norms, including through the use of patient and profes-
sional stories.
4. Encourage practices to plan and organise the inte-
gration of work associated with reviewing targeted pre-
scribing into practice processes, including the definition
of responsibilities of different practice members.
The educational intervention will be delivered via an
initial educational outreach visit just before intervention
start with an offer of a follow-up visit after approximately
three months, and via written material available via the
DQIP informatics tool (brief reminders when presenting
data, links to more comprehensive documents).
Intervention component three: Financial incentives to
review patients
Historically, trials of this nature have included payment
to practices for the time taken to participate in the
research, paid via NHS Support Costs. Typically, prac-
tices are paid based on an estimate of the time involved.
For DQIP, we have chosen to structure the ‘NHS Sup-
port Costs’ as an explicit financial incentive to review
patients, with payments modelled on existing general
practice ‘enhanced service’ contracts (specific payments
beyond capitation for particular services).
Practices will receive a fixed payment of 350 GBP (560
USD; 403 EUR) for participation and providing data,
which is paid before the start of the trial. An important
aim of this payment is so that practices agreeing to take
part have received a payment while waiting to actually
start the intervention; in addition, Practices will receive
a payment of 15 GBP (24 USD; 17 EUR) per patient
reviewed, where practices earn one payment for each
patient reviewed in the year of follow-up rather than
payment for every review. This payment will be pro-
vided at the end of the trial.
It is critical to note is that there is no financial incen-
tive to change prescribing because this remains comple-
tely subject to the clinical judgement of the caring
clinician after discussion with the patient. The time line
of processes that each cohort of practices will receive as
part of the DQIP intervention is shown in Appendix 1.
Recruitment of general practices
General practices with compatible IT systems in the two
health boards will be identified through each board’s IT
department. All eligible practices (practice manager and
all general practitioners in each practice) will receive an
email, which informs them of the DQIP trial before formal
recruitment starts. This email informs practices of the pur-
pose of the trial and of dates and venues of further infor-
mation meetings to be held in four different locations
across Tayside and Fife. The email will be followed by a
formal recruitment letter accompanied by an attractive
information sheet that summarises trial processes. The let-
ter will be framed as opt-in to study/opt-out of study and
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an invitation to request a practice visit by the research
team or a phone call to discuss. Practices who do not
respond to this letter will receive a phone call. From
practices that express an interest, we will obtain
informed consent to take part, extract data, and rando-
mised each practice to a start date. Up to three months
before the start date in each practice, we will confirm
consent to take part and to extract data, as well as obtain
a list of professionals who are to have access to the
informatics tool.
Recruitment of patient participants
While the DQIP IT tool (intervention component one)
will identify patients who are affected by targeted high-
risk prescribing, it will be at each practice’s discretion
whether and when these patients’ prescribing is
reviewed and how changes in prescribing (if any) are
implemented. This may include writing a letter to the
patient, inviting the patient to make an appointment for
a phone or face-to-face consultation, or to flag the notes
to increase awareness of high-risk prescribing the next
time the patient attends. All relevant prescribing deci-
sions and follow-up actions will be recorded in the
DQIP IT tool and payment for reviews issued, irrespec-
tive of the decisions made (see intervention component
three: financial incentives).
Trial objectives
We hypothesise that the DQIP intervention will reduce
rates of high-risk prescribing compared to usual prac-
tice. The specific objectives are:
1. To test the effectiveness of the DQIP intervention
in reducing the specified primary outcome of a compo-
site measure of high-risk non-steroidal anti-inflamma-
tory drug and antiplatelet prescribing.
2. To test the effectiveness of the DQIP intervention
in reducing the specified secondary outcomes of: the
nine individual measures constituting the composite;
related admissions to hospital; repeat versus new
prescribing.
3. To assess the cost-effectiveness of the intervention.
Sample size
In the pilot practices that targeted high-risk NSAID and
antiplatelet prescribing, there was a 40% reduction in
this prescribing after one round of feedback and review.
This is similar to the short-term reduction in high-risk
prescribing achieved in the recently completed PINCER
trial [16]. We therefore consider a 20% reduction in
high-risk prescribing as measured by our outcome mea-
sures plausible (and relatively conservative), and have
used this in the power calculation. Power calculations
for stepped wedge trials are relatively complex, and
three estimates are presented.
Practice level analysis
The first assumes a practice level analysis, which is the
most conservative. Estimated standard deviations are
taken from the measured SD in the PINCER trial, and
baseline was estimated from a general practice clinical
dataset. The number of practices required is estimated
to detect a 20% reduction from baseline with power of
80% with a two-sided alpha of 0.05 (Table 1).
Patient level analysis
The second estimate assumes that patient level before
and after data is available, and 15 practices are esti-
mated to be needed. The third assumes a patient level
analysis with time series data available, with three
‘before’ and three ‘after’ data points. Power is clearly
adequate with approximately 10 practices (Table 2).
From this analysis, it is clear that lack of power is not
likely to be an issue. Because we know that there are
significant differences between the two health boards in
the primary care pharmacy resource available to prac-
tices, we expect to see differences in the effect size
between Boards. Additionally, the literature indicates
that interventions of the kind planned often (but not
always) have varying effects in larger versus smaller
practices. This therefore allows us to plan for well pow-
ered within strata analyses, and we plan to stratify ran-
domisation into four strata (the combination of the two
binary variables Tayside versus Fife and larger versus
smaller) with 10 in each strata.
Randomisation and allocation concealment
The practice will be the unit of allocation, with practices
randomised to an intervention start date using a stepped
wedge design. On the assumption that forty practices
are recruited, four practices will be allocated to each
start date, and randomisation will be stratified in order
to ensure balance across time points in terms of:
1. Health board (NHS Tayside and NHS Fife). The
rationale is that the underlying organisational context
differs, particularly in the way that primary care phar-
macy and prescribing advice is organised, and in the
focus of prescribing improvement work.
2. List size (larger versus smaller practices). The ratio-
nale is that there is evidence that complex interventions
may be more difficult to implement in larger practices
[19]
Table 1 Sample size estimation for practice level analysis
Standard
Deviation
Difference 10% to
8%
Effect
size
Number of
practices
4.0% 2.0% 0.500 34
6.0% 2.0% 0.333 73
7.0% 2.0% 0.286 96
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3. The stepped wedge randomisation will be compu-
ter-generated by the statistician on the project (PD)
blinded to practice identity, subsequent to which the
core research team (TD, AG, and BG) and participating
practices will be informed of their start date.
Blinding
Due to the nature of the intervention, it is not possible
to blind either practices or the core research team (TD,
AG, and BG). However, outcome assessment is entirely
objective and automated. It is also not possible to blind
the analyst because the analysis is a time series in which
every practice receives the intervention rather than a
comparison between groups. The main analysis will
therefore be pre-specified rather than blinded, and any
analysis not pre-specified will be clearly identified as
such and therefore hypothesis generating/exploratory
rather than hypothesis testing/explanatory.
Outcome measures
The outcome measures used are shown in detail in
Tables 3, 4, 5, 6, 7 and the levels of analyses (practice
versus patient level) are outlined under ‘statistical
methods’.
Primary outcome measure
Table 3: Primary outcome measure (CPO = Composite
of prescribing outcomes)
Secondary outcome measures
Prescribing outcome measures-individual measures
Table 4: Secondary outcome measures (PO = Prescrib-
ing outcomes)
’Repeated’ versus ‘New’ prescribing Table 5: Secondary
outcome measures (repeated versus new prescribing)
Admission outcome measures
Table 6: Secondary outcome measures (AO = admis-
sions outcomes)
Measures of wider impact on NSAID prescribing
Table 7: Measures of wider impact on NSAID prescrib-
ing (VO = volume outcomes)
Cost-effectiveness
The cost-effectiveness of the intervention will be mea-
sured as the cost per reduction in high-risk prescribing
and cost per reductions in hospitalisations from an NHS
perspective.
Data collection
Prescribing outcomes (PO - 1 to 9)
The primary outcome and prescribing secondary out-
comes will be measured in each practice at eight weekly
intervals (reflecting that the measure numerators are all
for high-risk prescriptions in the last eight weeks). At
the time of initial data extraction, eight weekly measures
will be constructed for the 48 weeks before the interven-
tion start date.
All outcomes will be measured in the informatics
tool using identifiable patient data, but only practices
will be able to view identifiable data which will remain
in an NHS Tayside controlled database. Access to
identifiable data will require explicit practice consent
for each individual using the tool, and will be con-
trolled by the NHS Tayside LDAP system used for all
clinical systems.
During the study, the core research team will be able
to view aggregate practice data (run charts of change
over time for each measure) and a summary of practice
activity (log-ins, reviews, actions taken). At the end of
the trial, fully anonymised data will be extracted from
the informatics tool database held by NHS Tayside, and
transmitted to the research team using established Uni-
versity of Dundee Health Informatics Centre (HIC)
Standard Operating Procedures (SOPs) that require
robust anonymisation, transmission using appropriate
secure encryption, storage of data on securely encrypted
computers, and compliance with Data Protection Act
regulations.
Admission outcomes (AO - 1 to 9)
Scottish Morbidity Recording (SMR01) data on admis-
sions will be linked by HIC to the prescribing data sup-
plied by Aridhia, and provided to the research team
under the conditions required by the HIC SOPs
described above.
Table 2 Sample size estimation for patient level analysis
with time series data
Number of practices Effect size Power
10 0.25 83%
10 0.50 97%
10 0.75 99%
10 > 1.0 > 99%
Table 3 Primary outcome measure (CPO = Composite prescribing outcome)
Number Risk factor (Denominator) High-risk prescription definition (Numerator)
CPO Number of patients with any risk factor listed in PO-measures 1
to 9 (Table 4)
Number of patients with any high-risk prescription listed in PO-measures 1
to 9 (Table 4)
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Statistical methods
The analyses will be implemented under the principle of
intention-to-treat and the guiding principles of the ICH
E9 for the analysis of randomised controlled trials. All
analyses will be carried out under the guidance of the
Tayside Clinical Trials Unit, which has UK registration.
The stepped wedge design is essentially a matched
design with before and after comparisons for each unit
of randomisation. In this case, the unit will be a group
of practices where each group is randomised to a parti-
cular starting time. In addition to practice level, patient
level data will also be collected, and so the analysis is
divided into practice level and patient level with the
patient level analysis as the primary outcome.
Practice level analysis
Practices will be characterised by health board, size, age
range, proportion of men and women, number of GPs,
and training status. The primary outcome of the compo-
site high-risk prescribing measure (Table 3) will be sum-
marised as the mean and standard deviation across
practices for before and after the intervention started.
Analysis of before compared to after intervention will be
carried out using mixed models or multi-level models
that account for the correlation of repeated measures
(eight-week periods) and stratification by health board
in two levels (Tayside and Fife; larger and smaller list
sizes). The primary null hypothesis is no difference in
the composite before compared to after intervention. A
Table 4 Secondary outcome measures (PO = Prescribing outcomes)
Number Risk factor (Denominator) High-risk prescription definition (Numerator)
PO-
1
Number of patients with a Read Code for peptic
ulceration ever recorded
Number of denominator patients prescribed a traditional oral NSAID¶ or low dose
aspirin in the previous eight weeks who have NOT been prescribed a gastro-
protective drug in the 12 weeks before, or since the most recent NSAID or aspirin
prescription
PO-
2
Number of patients aged 75 and over Number of denominator patients prescribed a traditional oral NSAID¶ in the previous
eight weeks who have NOT been prescribed a gastro-protective drug in the 12
weeks before, or since the most recent NSAID prescription
PO-
3
Number of patients aged 65 and over prescribed aspirin
in the previous 12 weeks
Number of denominator patients prescribed a traditional oral NSAID¶ in the previous
eight weeks who have NOT been prescribed a gastro-protective drug in the 12
weeks before, or since the most recent NSAID or aspirin prescription
PO-
4
Number of patients aged 65 and over prescribed aspirin
in the previous 12 weeks
Number of denominator patients prescribed clopidogrel in the previous eight weeks
who have NOT been prescribed a gastro-protective drug in the 12 weeks before, or
since the most recent aspirin or clopidgrel prescription
PO-
5
Number of patients prescribed warfarin in the previous
12 weeks
Number of denominator patients prescribed a traditional oral NSAID¶ in the
previous eight weeks who have NOT been prescribed a gastro-protective drug in
the 12 weeks before, or since the NSAID prescription
PO-
6
Number of patients prescribed warfarin in the previous
12 weeks
Number of denominator patients prescribed low dose aspirin or clopidogrel in the
previous eight weeks who have NOT been prescribed a gastro-protective drug in
the 12 weeks before, or since the aspirin or clopidogrel prescription
PO-
7
Number of patients with a QOF heart failure code ever
recorded
Number of denominator patients prescribed any oral NSAID in the previous eight
weeks
PO-
8
Number of patients prescribed both a diuretic and an
ACE inhibitor/ARB in the previous 12 weeks
Number of denominator patients prescribed any oral NSAID in the previous eight
weeks
PO-
9
Number of patients with a QOF CKD (stage 3, 4, or 5)
code recorded as the most recent CKD code
Number of denominator patients prescribed any oral NSAID in the previous eight
weeks
PO-
10
GI risk composite
Number of patients with any risk factors as defined in
PO-measures 1 to 6
Number of denominator patients with any high-risk prescription as defined in PO-
measures 1 to 6
PO-
11
Renal risk composite
Number of patients with any risk factors in PO-measures
8 to 9
Number of denominator patients with any high-risk prescription as defined in PO-
measures 8 to 9
¶ ’Traditional’ NSAID means all representatives of this class except Cox-2 selective agents, such as celecoxib;
Key: NSAID = Non-steroidal anti-inflammatory drug; QOF = Quality and outcomes framework; CKD = chronic kidney disease; ACE = angiotensin converting
enzyme; ARB = Angiotensin Receptor Blocker
Table 5 Secondary outcome measures (Repeated versus new prescribing)
Number Risk factor (Denominator) High-risk prescription definition (Numerator)
CPO-
Repeated
Number of patients with any risk factor listed
in PO-measures 1 to 9 (Table 4)
Number of patients with any high-risk prescription listed in PO- measures 1 to 9 (Table
4) where the patient has received a high-risk prescription in the previous 12 months
CPO-
New
Number of patients with any risk factor listed
in PO-measures 1 to 9 (Table 4)
Number of patients with any high-risk prescription listed in PO-measures 1 to 9 (Table 4)
where the patient has NOT received a high-risk prescription in the previous 12 months
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test of the intervention (before versus after) by health
board interaction in the model will test whether results
differ by health board. Mixed models have the advantage
of allowing for missing data while maintaining the prin-
ciple of intention to treat (ITT). These models can also
incorporate adjustment for baseline differences. The
practice level analyses will be secondary to the patient
level analyses. This will be repeated for all secondary
measures (Tables 4 to 7).
Patient level analysis
The analysis above will be repeated including patient
level as well as practice level data. This will be the pri-
mary analysis. At the patient level, the primary outcome
is binary (yes, no), and so mixed models with binary
outcomes will be utilised, i.e., non-linear mixed models.
These incorporate the correlation of patients within
practices and of repeated measurements over time. At
the patient level, descriptive measures will be tabulated
such as age, gender, deprivation decile of Scottish Index
of Multiple Deprivation (SIMD), number of measures
that are relevant to a patient (i.e., the patient meets the
denominator definition), as well as the primary and sec-
ondary outcomes as percentages.
The mixed model will incorporate fixed terms for
intervention (before versus. after), time (eight-week time
periods) as well as the correlation of patients within
practices and the correlation of repeated measurements
over time as random effects. Hence, the analysis will
have the element of time series analyses with multiple
time points before and after intervention. The primary
null hypothesis is no difference in the composite before
compared to after intervention as a binary factor.
Because patients can be in more than one time period
and move in and out of numerators and denominators,
the correlation of repeated measures for these
Table 6 Secondary outcome measures (AO = Admissions outcomes)
Number Denominator Numerator
Trigger event plus high-risk prescription
Specific hospital admissions that were preceded by high-risk prescribing
AO-1 Patient time with GI risk factors as defined in
PO- measures 1 to 6 (Table 4) #
Number of denominator patients admitted with GI bleeding who had any high risk
prescription as defined in PO-measures 1 to 6 (Table 4) in the eight weeks before
admission
AO-2 Patient time with heart failure as defined in
PO-measure 7 (Table 4) #
Number of denominator patients admitted to hospital for HF - exacerbation who had a
high-risk prescription as defined in PO-measure 7 (Table 4) in the eight weeks before
admission
AO-3 Patient time with renal risk factors as defined
in PO-measures 8 to 9 (Table 4)#
Number of denominator patients admitted to hospital for acute renal failure or with
dehydration or diarrhoea (both defined as potentially inappropriate/ambulatory care
sensitive admissions) who had any high-risk prescription as defined in PO-measures 8 to
9 (Table 4) in the eight weeks before admission
Specific hospital admissions irrespective of high-risk prescribing
AO-4 Patient time with GI risk factors as defined in
PO-measures 1 to 6 (Table 4)#
Number of denominator patients, who are admitted to hospital for GI bleeding
AO-5 Patient time with heart failure as defined in
PO-measure 7 (Table 4)#
Number of denominator patients, who are admitted to hospital for HF - exacerbation
AO-6 Patient time with renal risk factors as defined
in PO-measures 8 to 9 (Table 4)#
Number of denominator patients, who are admitted to hospital for acute renal failure or
with dehydration or diarrhoea (both defined as potentially inappropriate/ambulatory care
sensitive admissions)
Any cause hospital admissions
AO-7 Patient time with GI risk factors as defined in
PO-measures 1 to 6 (Table 4)#
Number of denominator patients admitted to hospital with any emergency admission
AO-8 Patient time with heart failure as defined in
PO-measure 7 (Table 4)#
Number of denominator patients admitted to hospital with any emergency admission
AO-9 Patient time with renal risk factors as defined
in PO-measures 8 to 9 (Table 4)#
Number of denominator patients admitted to hospital with any emergency admission
# The denominator is the time that each patient is defined as having risk factors by virtue of age, disease or co-prescribing in the year before the intervention
and the year of follow-up. AO measures 1 to 3 consider specific hospital admissions where patient has had a recent high-risk prescription; AO measures 4 to 6
consider specific hospital admissions irrespective of whether or not the patient has a had a recent high-risk prescription; AO measures 7 to 9 consider all
emergency admissions
Table 7 Measures of wider impact on NSAID prescribing (VO = Volume outcomes)
VO-1 Total NSAID prescription volume/registered patients in participating compared to non-participating practices
VO-2 Proportion of patients prescribed an NSAID stratified by age in participating compared to non-participating practices
Key: NSAID = Non-steroidal anti-inflammatory drug
Dreischulte et al. Implementation Science 2012, 7:24
http://www.implementationscience.com/content/7/1/24
Page 9 of 13
individuals will be taken into account in the multilevel
modelling. Patients are nested within practices but can
be cross-classified with respect to time periods. Initially,
this cross classification will be ignored and then the
analyses will be repeated with cross-classification terms
to assess any differences. These analyses will be repeated
for all secondary outcomes.
A formal statistical analysis plan will be documented
prior to data lock, and this will form the detailed proto-
col for analysis. All analyses will be carried out using
SAS 9.2 and SPSS v18.
Discussion
Although IT-based interventions that identify and target
patients with high-risk prescribing for review have pre-
viously shown to be potentially effective, there is a need
for approaches that are more economically sustainable
and produce longer-term effects. The DQIP intervention
makes use of the existing NHS IT-infrastructure to con-
tinuously identify patients with high-risk prescribing and
is targeted at existing practice teams rather than relying
on additional professional time/resource, which has
obvious advantages, especially in the current financial
climate.
Assumptions underlying the design of the DQIP
intervention
The design of the DQIP intervention is based on the
assumption that in order to be effective in reducing
high-risk prescribing of NSAIDs and antiplatelets, then:
The intervention has to be adopted by practices.
Adoption is the process by which clinicians and prac-
tices are persuaded that the change promoted by the
intervention is worth pursuing, that the intervention
itself is likely to lead to benefit, and to then ensure that
the intervention is implemented. The DQIP intervention
aims to support adoption by providing education, an
initial fixed payment of 350 GBP (560 USD; 403 EUR),
and email reminders to those practices with minimal
use of the DQIP tool.
Practices have to reach patients. A necessary condition
for the intervention to work is that it is actually delivered
to the right patients at the right time. This requires prac-
tices to identify suitable patients to deliver the intervention
to. If reach is low, then few patients will receive the inter-
vention, and overall effectiveness will also be low irrespec-
tive of how ‘effective’ the intervention is in patients who
actually receive it. The DQIP intervention aims to support
reach by timely and continuous identification of patients
affected by high-risk prescribing, by email -reminders to
practices to review their data, and by offering payment of
15 GBP (24 USD; 17 EUR) per patient reviewed.
Practices have to deliver the intervention effectively to
patients who are reached. In DQIP, this implies that the
way of reviewing and making decisions about high-risk
prescribing have to be plausibly effective in reducing the
likelihood of adverse drug events from NSAIDs and
antiplatelets. The DQIP intervention aims to support
effective delivery by structuring clinical information to
facilitate review and by alerting practitioners to situa-
tions, where patients are re-prescribed high-risk medica-
tion against previously documented intentions.
Practices have to maintain these processes for the
duration of the trial. A feature of the PINCER study was
that 12-month impact of a one-off pharmacy led review
was smaller than the six-month effect [20]. In other
words, the intervention effect was not fully maintained,
either because new patients were prescribed the targeted
drugs, or because patients restarted them, or both.
Long-term effectiveness requires that the intervention is
maintained. The DQIP intervention aims to support
maintenance by continuous (rather than one-off) identi-
fication of patients affected by high-risk prescribing over
the whole duration of the trial, by monitoring whether
any improvements in high-risk prescribing are main-
tained over time (run chart) and alerting practices if this
is not the case, and by payment of 15 GBP (24 USD; 17
EUR) per patient reviewed (rather than one-off).
Design of outcome measures
The DQIP intervention is designed to change prescrib-
ing behaviour in primary care and thus, our primary
outcome measure and the majority of secondary out-
come measures are designed to reflect such behaviour
changes.
The core of the intervention is to review existing high-
risk prescribing, but we are also hypothesising a reduc-
tion in ‘new’ prescribing, via the triggering of internal
practice processes similar to those that appear to have
happened with QOF, where stimulating internal moni-
toring/surveillance have been important mediators of
change [21-24]. We do not have any direct control over
these internal processes, but will explore their impact by
measuring both change in existing prescribing (patients
who have received a targeted high-risk prescription in
the previous 12 months) and change in ‘new’ prescribing
(patients receiving a targeted high-risk prescription who
have not received one in the previous 12 months).
Although not a primary outcome in this trial, the
ultimate aim of changing practitioner behaviour is to
improve outcomes for patients. However, prescribing
is only one among other healthcare process that (in
addition to patients ’ underlying risk factors) may
influence outcomes, which implies that interventions
focussing on medication use only are unlikely to sig-
nificantly alter overall mortality or hospital admission
rates. Nevertheless, such outcome measures have been
used in a number of trials seeking to assess the impact
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of medication review interventions [25]. We have
therefore designed measures that may more specifi-
cally capture the potential impact of the DQIP inter-
vention on patient outcomes, i.e., NSAID and
antiplatelet specific hospital admissions that are pre-
ceded by high-risk prescribing of these agents (AO 1
to 3). Because state-of-the-art assessment of causality
and preventability of adverse drug events over the
duration of a trial is usually not feasible (clinical jud-
gement by two or more independent experts is usually
required), the outcome measures of the type used
here may inform the design of similar trials of inter-
ventions seeking to improve and measure changes in
drug therapy outcomes.
Rationale for employing the stepped wedge design
The stepped wedge is a relatively novel design for the
evaluation of health service interventions. We have cho-
sen this design for two main reasons. First, the staggered
entry of practices into the study has logistic advantages
in the delivery of the educational outreach visit. If forty
practices are recruited, then four practices will start the
intervention every four weeks. In contrast, starting all
intervention-arm practices at once under a conventional
design is not feasible within the resources of our
research team. Second, we anticipated a high dropout
rate of practices that would have otherwise been rando-
mised to the ‘care as usual arm’ under a conventional
two arm design, because we would not have been able
Table 8 Process for each participating practice
TIME
(weeks)
ACTIVITY
While waiting
for
intervention
Bimonthly newsletter about trial progress; reminder about start date Fixed payment of 350 GBP (560 USD; 403 EUR) (Intervention
component 3)
Intervention
minus 12
Contact to organise dates for practice training visit; identify who is going to have access to the informatics
Intervention
start
Access to informatics turned on (Intervention component 1); Email notification Educational outreach visit (Intervention component
2)§
Ask practice to nominate a lead GP as the main practice contact
Intervention
plus 4
For practices with minimal use of the tool: Email to lead GP asking for reason and offer further support (IT, clinical, administrative) or
practice visits
Intervention
plus 8
E-mail newsletter, report on their use of the tool and on changes in their prescribing (positive encouragement irrespective of data,
but framed by it). §
For practices with minimal use of the tool: Email to lead GP asking for reason and offer further support (IT, clinical, administrative) or
practice visits
Intervention
plus 12
Offer second practice visit
Intervention
plus 16
E-mail newsletter, report on their use of the tool and on changes in their prescribing (positive encouragement irrespective of data,
but framed by it). §
For practices with minimal use of the tool: Email to lead GP asking for reason and offer further support (IT, clinical, administrative) or
practice visits
Intervention
plus 24
E-mail newsletter, report on their use of the tool and on changes in their prescribing (positive encouragement irrespective of data,
but framed by it). §
For practices with minimal use of the tool: Email to lead GP asking for reason and offer further support (IT, clinical, administrative) or
practice visits
Intervention
plus 32
E-mail newsletter, report on their use of the tool and on changes in their prescribing (positive encouragement irrespective of data,
but framed by it). §
For practices with minimal use of the tool: Email to lead GP asking for reason and offer further support (IT, clinical, administrative) or
practice visits
Intervention
plus 40
E-mail newsletter, report on their use of the tool and on changes in their prescribing (positive encouragement irrespective of data,
but framed by it). §
For practices with minimal use of the tool: Email to lead GP asking for reason and offer further support (IT, clinical, administrative) or
practice visits
Intervention
plus 44
E-mail report, two months to go, encourage final review
Intervention
plus 48
E-mail report, one month to go, encourage final review
Intervention
plus 52
Thank you, final report on what they did, Payment of 15 GBP (24 USD; 17 EUR) (Intervention component 3)
Intervention
plus 4 to 48
Practices are notified of any significant new evidence or guidance relating to targeted high-risk prescribing
§ Encouragement to contact the DQIP team if questions arise or problems occur. The DQIP team will meet any request for further support (IT, clinical,
administrative) or practice visits
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to provide the same financial incentives to these prac-
tices, but would have still required these practices’ out-
come data. We hope that the fact that all participating
practices will receive the intervention will facilitate
recruitment and reduce drop-out rates [17].
A welcome side effect of the stepped wedge design is
that because practices serve as their own controls, the
total sample size required for the trial is lower than
under a conventional two-arm design (theoretically, a
sample size of ten practices would have sufficed for
patient level analysis). Recruiting more practices will
support the external validity of findings by ensuring that
a more representative range of practices participate and
to allow examination by strata.
Anticipated challenges
Despite these advantages, we anticipate a number of
challenges. The staggered entry into the trial implies
that practices randomised to a later start date will start
the intervention up to one year after their initial consent
to participate, which implies the risk that initial motiva-
tions of practices to take part may no longer be valid at
their allocated starting date. We have therefore defined
a strategy to maintain the interest of practices while
they are waiting to start the DQIP intervention (see
Table 8).
A further potential problem in stepped wedge designs
is contamination between intervention participants and
those waiting for the intervention. It is possible that
some practices will change their prescribing behaviour
as a consequence of being alerted to high-risk NSAIDs
and antiplatelet prescribing during recruitment. How-
ever, we expect such effects to be mild in comparison to
the DQIP intervention because meaningful and sus-
tained reductions in the targeted high-risk prescribing
will require systematic and prolonged effort that is unli-
kely to occur before the DQIP tool is implemented [16].
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